4771-07-7

Usage

Uses

Used in Pharmaceutical Industry:
2'-METHYL-5'-NITROBENZANILIDE is used as a chemical intermediate for the synthesis of pharmaceuticals. Its unique chemical structure allows it to be a key component in the development of new drugs and medicines.
Used in Dye Industry:
2'-METHYL-5'-NITROBENZANILIDE is used as a chemical intermediate in the synthesis of dyes. Its ability to participate in various chemical reactions makes it a valuable component in creating a wide range of dyes for different applications.
Used in Organic Chemistry Research:
2'-METHYL-5'-NITROBENZANILIDE is used as a building block in organic chemistry research. Its potential for creating more complex molecules and its involvement in various chemical reactions make it a promising candidate for scientific studies and the development of new organic compounds.
Used in Potential Pharmacological Applications:
2'-METHYL-5'-NITROBENZANILIDE has been studied for its potential pharmacological properties. It is being investigated for its potential use in the treatment of certain diseases, making it a promising candidate for further research and development in the field of medicine.

InChI:InChI=1/C14H12N2O3/c1-10-7-8-12(16(18)19)9-13(10)15-14(17)11-5-3-2-4-6-11/h2-9H,1H3,(H,15,17)

Upstream product

• 98-88-4 benzoyl chloride 
• 99-55-8 2-methyl-5-nitroaniline 

Downstream Products

• 223138-39-4 N-(2-methyl-5-aminophenyl)benzamide 
• 1192928-01-0 N-3-(benzoylamino-4-methylphenylaminocarbonothioyl)-3,4,5-trimethoxybenzamide 
• 1263131-95-8 N-(N-(3-Bbenzamido-4-methylphenyl)carbamimidoyl)-3,4,5-trimethoxybenzamide hydrochloride 
• 1374006-61-7 C₂₄H₁₈N₂O₄ 
• 1374006-60-6 C₁₉H₁₇N₃O₃ 
• 328959-39-3 C₂₃H₂₀N₂O₄ 
• 1374006-59-3 C₂₂H₁₆ClF₃N₂O₂ 
• 1374006-57-1 C₂₃H₁₆F₆N₂O₂ 
• 1374006-51-5 C₂₀H₁₇ClN₄O₂ 
• 1374006-50-4 C₂₃H₂₁N₃O₄ 
• 1374006-49-1 C₂₂H₁₉N₃O₄ 
• 1374006-48-0 C₂₇H₂₃N₃O₃ 
• 1374006-47-9 C₂₃H₂₁N₃O₃ 
• 1374006-46-8 C₂₃H₂₃N₃O₂ 

Relevant academic research and scientific papers

Synthesis, spectroscopic analysis and DFT studies of N-(2-methyl-5-nitro-phenyl)benzamide organic single crystal

N-(2-methyl-5-nitro-phenyl)benzamide (N2M5NPBA) compound was synthesized by benzoylation of 2-methyl-5-nitroaniline. N2M5NPBA single crystal was grown by slow evaporation technique using DMSO as solvent. Single crystal X-ray diffraction study of N2M5NPBA

New diarylureas and diarylamides possessing acet(benz)amidophenyl scaffold: Design, synthesis, and antiproliferative activity against melanoma cell line

A series of new diarylurea and diarylamide derivatives possessing acet(benz)amidophenyl scaffold was synthesized. Their in vitro antiproliferative activity was tested against A375P human melanoma cell line. Compounds 1c,d and 2c,d showed the highest potencies with IC50 values in sub-micromolar scale. In addition, compounds 1b,e,l and 2e,l were more potent than Sorafenib but with IC50 values in micromolar range. Moreover, compound 2c was equipotent to Vemurafenib, and 2d showed higher potency than Vemurafenib against A375P. Molar refractometry calculation and ADME profiling of the highest potent four derivatives 1c,d and 2c,d are also reported.

Design, anticonvulsive and neurotoxic properties of retrobenzamides / N- (nitrophenyl)benzamides and N-(aminophenyl)benzamides

Design, anticonvulsant properties in maximal electroshock-reduced seizures [MES] and seizures reduced by subcutaneous administration of pentetrazole (scPtz), and neurotoxicity of retrobenzamides (N- (nitrophenyl)benzamides and N-(aminophenyl) benzamides are reported. These data are further compared with those on carbamazepine, phenytoin, ameltolide and other reference compounds. Studies on retrobenzamides in mice dosed intraperitoneally point out a good anticonvulsant potential in the MES test for the amino derivatives (N-(aminophenyl)benzamides) and moderate activity for corresponding 'nitro' derivatives. In rats dosed orally, aminoretrobenzamides were, however, less active in the MES test than in mice dosed intraperitoneally. Differences between experimental animal species and administration routes lead to hypothesize rapid metabolization of compounds, reduced intestinal resorption and increased removal from body. The presence of a methyl substitution on the N-phenyl moiety of aminoretrobenzamides attenuated these discrepancies between mice and rats. Present results indicate that pharmacological values - including the dose offering anticonvulsant protection in 50 % of tested animals (ED50) and protective indices - obtained on some retrobenzamides may compete with phenytoin and carbamazepine values. By contrast with phenytoin, some retrobenzamides further exhibit activity in the scPtz test.